;

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Finance > US FDA approves Sanofi's bleeding disorder therapy

Finance

US FDA approves Sanofi's bleeding disorder therapy

Published by Global Banking and Finance Review

Posted on March 28, 2025

Featured image for article about Finance

(Reuters) -The U.S. Food and Drug Administration approved French drugmaker Sanofi's therapy, paving the way for a new type of treatment for patients 12 years of age and older with a rare disorder that prevents blood from clotting properly, the regulator said on Friday.

(Reporting by Padmanabhan Ananthan and Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)

More from Finance

Explore more articles in the Finance category

Russia's central bank seeks $230 billion in damages from Belgium's Euroclear, Moscow court says

EU to broaden Belarus sanctions to include hybrid activity, Lithuania says

Stocks slip ahead of central bank decisions, key data

Analysis-Old meets new economy: AI boom to supercharge European banks' rally

Bank of England heads for close vote on likely rate cut

EU yields to pressure from automakers as it rethinks 2035 combustion car ban

Analysis-Wild currency swings put emerging markets in the spotlight

Yen gains ahead of BOJ meet as investors gird for busy week

Oil rises as Venezuelan supply disruptions outweigh surplus concerns

UK regulation of cryptoassets to start in October 2027, finance ministry says

Russia says it destroyed 130 Ukrainian drones overnight, some Moscow airports disrupted

Released Belarus prisoners have no regrets over their actions

View All Finance Posts